NSB 2.50% 3.9¢ neuroscientific biopharmaceuticals ltd

It's probably a non-issue since the Early-Phase Clinical Trial...

  1. 1,216 Posts.
    lightbulb Created with Sketch. 1375
    It's probably a non-issue since the Early-Phase Clinical Trial is dosing up to 30 healthy volunteers. I have been following NSB due to its focus on neurodegenerative diseases and hope to one day see it tested to see if it improves outcomes for these patients.
 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.